Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8227883 | 0.90 | CACNA1H (0.47) | HDAC1HDAC6 | |
| SCHEMBL8213178 | 0.85 | TRPV1 (0.48) | CYP2D6TSHRTRPV1USP2CYP3A4 | |
| SCHEMBL8200179 | 0.84 | TSHR (0.47) | TSHRALOX15TRPV1GPR119ATM | |
| SCHEMBL8208288 | 0.83 | HDAC1 (0.47) | HDAC1HDAC6TSHRALOX15TRPV1 | |
| SCHEMBL8224879 | 0.83 | HDAC1 (0.44) | HDAC1HDAC6TSHRALOX15TRPV1 | |
| SCHEMBL8227850 | 0.82 | HDAC1 (0.45) | HDAC1HDAC6TSHRALOX15TRPV1 | |
| SCHEMBL8212694 | 0.82 | TRPV1 (0.61) | HDAC1HDAC6TSHRALOX15TRPV1 | |
| SCHEMBL8218899 | 0.82 | GPR119 (0.48) | HDAC1HDAC6TSHRALOX15TRPV1 | |
| SCHEMBL8218912 | 0.82 | HDAC1 (0.46) | HDAC1HDAC6TRPV1GPR119TACR1 | |
| SCHEMBL8217835 | 0.79 | TRPV1 (0.55) | TSHRALOX15TRPV1GPR119ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | HDAC1 937/4885HDAC6 2818/4885CYP2D6 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.